TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc. (Nasdaq: TELA) on October 4, 2025. The report discloses changes to the composition of the Board of Directors, specifically the resignation of one director and the appointment of another.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
- Resignation: Lisa Colleran resigned from the Board of Directors, the Nominating and Corporate Governance Committee, and the Audit Committee, effective October 4, 2025. The resignation was not due to any disagreement with the Company.
- Appointment: Dr. Betty Jo Rocchio was appointed to the Board, effective October 9, 2025. She serves as a Class I director with a term expiring at the 2026 Annual Meeting of Stockholders.
- Background: Dr. Rocchio is currently the Executive Vice President and Chief Executive Nurse at Advocate Health, overseeing 165,000 employees. She is considered an independent director under Nasdaq rules.
Compensation and Outlook
The Board granted Dr. Rocchio an initial equity award and established her annual compensation package:
- Initial Equity Award (Oct 9, 2025):
- Option to purchase 17,550 shares of Common Stock, vesting in 36 equal monthly installments.
- Restricted Stock Units (RSUs) for 11,925 shares, vesting in three equal annual installments.
- Annual Base Retainer: $45,000.
- Future Annual Awards (Starting 2026):
- Option to purchase 11,700 shares of Common Stock.
- RSUs for 7,950 shares of Common Stock.
- Vesting occurs on the earlier of the first anniversary of the grant, the subsequent annual meeting, or a change in control.
The filing contains no specific guidance, outlook, or discussion of risks beyond standard compensation vesting conditions.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Rocchio's appointment (October 9, 2025) and her independence status.
- Verify the total number of shares authorized for issuance under the 2019 Equity Incentive Plan to assess dilution impact from the new awards.
- Review the Company's cash position to ensure it can support the $45,000 annual retainer and potential future equity grants.
- Monitor the composition of the Audit and Nominating Committees following Lisa Colleran's departure to ensure quorum and compliance.